MYO Platform (Infectious Disease)

About Renbio

RenBio is a private, preclinical-stage biotech developing a disruptive DNA delivery platform called MYO Technology. The platform encodes therapeutic proteins or antibodies in DNA, which is administered via intramuscular injection and electroporation, instructing the patient's muscle to become a bioreactor for sustained, in vivo drug production. This approach seeks to overcome key limitations of traditional biologics, including frequent dosing, high manufacturing costs, and cold-chain logistics. The company, co-founded by renowned virologist Dr. David Ho, is initially targeting infectious diseases and metabolic conditions like obesity, with the goal of creating longer-lasting, more accessible therapies.

Therapeutic Areas